Jazz Pharmaceuticals plc 8-K

What Happened
Jazz Pharmaceuticals plc (JAZZ) filed an 8-K on January 12, 2026 reporting that on January 13, 2026 the company will present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco. The presentation states the company expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025 and includes the company’s expectations for 2025 revenue for its key products Xywav, Epidiolex and Modeyso. A copy of the presentation slides was filed as Exhibit 99.1.

Key Details

• Filing date: January 12, 2026; presentation date: January 13, 2026 (J.P. Morgan Healthcare Conference).
• Company states it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025.
• Presentation includes revenue expectations for three products: Xywav, Epidiolex and Modeyso for the 2025 year.
• Presentation slides attached as Exhibit 99.1 to the 8-K.

Why It Matters
For investors, the company’s stated expectation to meet its full-year 2025 revenue guidance is a material operational update that reduces near-term uncertainty about top-line performance. Product-level revenue expectations for Xywav, Epidiolex and Modeyso highlight which franchises management is flagging as drivers of 2025 results; investors should review the attached slide deck (Exhibit 99.1) for the specific detail disclosed in the presentation.